Anran Song, Haiqing Yu, Changyuan Wang, Xingqi Zhu, Kexin Liu and Xiaodong Ma Pages 950 - 962 ( 13 )
Searching for safe and effective treatments for HIV infection is still a great challenge worldwide in spite of the 27 marketed anti-HIV drugs and the powerful highly active antiretroviral therapy (HAART). As a promising prospect for generation of new HIV therapy drugs, multiple ligands (MDLs) were greatly focused on recently due to their lower toxicity, simplified dosing and patient adherence than single-target drugs. Till now, by disrupting two active sites or steps of HIV replications, a number of HIV dual inhibitors, such as CD4-gssucap120 inhibitors, CXCR4-gp20 inhibitors, RT-CXCR4 inhibitors, RT-protease inhibitors, RT-integrase inhibitors, and RTassociated functions inhibitors have been identified. Generally, these dual inhibitors were discovered mainly through screening approaches and design strategies. Of these compounds, the molecules bearing small skeletons exhibited strong anti-HIV activity and aroused great attention recently. Reviewing the progress of the dual small-molecule HIV inhibitors from the point of view of their scaffolds and discovery strategies will provide valuable information for producing more effective anti-HIV drugs. In this regard, novel dual small-molecule HIV inhibitors were illustrated, and their discovery paradigms as the major contents were also summarized in this manuscript.
HIV Dual inhibitor, Small-Molecule scaffold, Design Strategy, DKA, Pyrimidinone, Phenprocoumon, HEPT-DKA, Coumarin- AZT, RT-CXCR4 Inhibitors, RT-Protease Inhibitors, RT-associated Functions Inhibitors.
College of Pharmacy, Dalian Medical University, No. 9, West Segment of South Lushun Road, Lushunkou District, Dalian, 116044, Liaoning Province, P.R. China.